{
    "2019-07-09": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Novo Nordisk Reports Encouraging Data From Hemophilia Studies",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Encouraging Data",
                        "Hemophilia Studies"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Would Novo Nordisk A/S (CPH:NOVO B) Be Valuable To Income Investors?",
                "features": {
                    "keywords": [
                        "Novo Nordisk A/S",
                        "Income Investors",
                        "Valuable"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}